PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

Purpose: PEGylation is widely used to improve nanoparticle drug and gene delivery by reducing aggregation, opsonization, and phagocytic clearance, thereby prolonging circulation. However, the field lacks a consolidated understanding of how PEG molecular weight, surface density, conformation, core properties, administration route, and repeated dosing affect delivery. This review addresses these gaps and discusses PEGylation beyond systemic administration, including mucosal, ocular, brain, gastrointestinal, and vaccine applications.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that PEG coatings on nanoparticles improve drug and gene delivery by sterically shielding surfaces and reducing non-specific biological interactions, but that efficacy depends critically on PEG molecular weight, surface density/conformation, nanoparticle core properties, route of administration, and immune recognition of PEG.

Aims: Describe the history and rationale of PEGylated nanoparticle formulations for systemic administration. - Review factors affecting circulation time of PEGylated nanoparticles, including PEG molecular weight, PEG content/surface density/conformation, and nanoparticle core properties. - Discuss PEGylation for reduced systemic toxicity and the immunogenicity of PEG, including accelerated blood clearance and PEG alternatives. - Highlight non-systemic applications of PEGylated nanoparticles, including vaginal, airway, gastrointestinal, brain, ocular, and vaccine delivery. - Summarize methods for nanoparticle PEGylation and quantification of PEG surface density.

Delivery system: System type: PEG-coated nanoparticles, including liposomes, polymeric nanoparticles, micelles, polyplexes, lipid nanoparticles, and inorganic nanoparticles. - PEG role: “Stealth” coating to reduce protein adsorption, opsonization, macrophage uptake, aggregation, and hemolysis; improve colloidal stability and circulation time. - Payloads discussed: Doxorubicin, paclitaxel, docetaxel, danazol, cyclosporine A, plasmid DNA, siRNA, mRNA, proteins, antigens, and vaccines. - Targeting/functional ligands: Transferrin, PSMA-targeting ligands, Fn14 antibody, folate, and others; often attached to PEG terminus. - Administration routes: Intravenous/systemic, vaginal, pulmonary/airway, gastrointestinal/oral, brain (direct/CED), ocular/topical/intravitreal, and subcutaneous/nasal vaccine routes. - Key PEG parameters: PEG molecular weight (e.g., 550 Da to 40 kDa), PEG surface density, mushroom vs. brush vs. dense brush conformation, and core material properties.

Approach: Review of in vitro, ex vivo, in vivo, and clinical literature. Model systems include human mucus, cystic fibrosis sputum, bovine vitreous, mouse/rat brain tissue, human plasma/serum, macrophage cell lines (THP-1, J774), dendritic cells, and animal models including mice, rats, and rabbits. Clinical examples include Doxil, CALAA-01, and BIND-014. No new primary experiments, group sizes, or doses are reported.

Key methods: Nanoparticle size, zeta potential, and colloidal stability. - Protein adsorption, opsonization, complement activation, and hemolysis assays. - Circulation half-life, biodistribution, and organ accumulation. - Multiple particle tracking in mucus, sputum, vitreous, and brain tissue. - NMR, fluorescence, XPS, anti-PEG antibody binding, and chromatography for PEG surface density quantification. - Transfection, gene silencing, and vaccine immune-response assays.

Key results: Doxil: PEGylated liposomal doxorubicin increased doxorubicin bioavailability nearly 90-fold at 1 week versus free drug; drug half-life 72 h, circulation half-life 36 h. - PEG molecular weight: Micelle circulation half-lives were 4.6, 7.5, and 17.7 min for 5, 10, and 20 kDa PEG, respectively. PEG ≥2 kDa generally required for shielding; higher MW can further reduce protein adsorption. - PEG surface density: Dense brush conformation was required for immune evasion. For polystyrene NPs, \(R_F/D > 2.8\) was needed for reduced macrophage uptake; in vivo, \(R_F/D > 6.6\) was needed for prolonged circulation, with only <20% removed at 2 h versus complete clearance for \(R_F/D \leq 4.2\). - Mucus penetration: Dense low-MW PEG coatings enabled rapid diffusion of 200 nm PS-PEG NPs in human cervicovaginal mucus; 10 kDa PEG immobilized particles. PLGA-PEG NPs with ≥5 wt% PEG penetrated mucus; low-density coatings did not. - Airway delivery: Densely PEGylated PBAE DNA nanoparticles (PBAE-MPP) penetrated CF sputum and distributed uniformly in mouse airways, whereas non-PEGylated PBAE-CP aggregated and cleared rapidly. - Brain delivery: Densely PEG-coated PS-PEG NPs up to 114 nm penetrated brain ECM. Paclitaxel-loaded PLGA-PEG NPs reduced tumor bioluminescence to 8% of control versus 45% for non-PEGylated PLGA and 85% for free paclitaxel. - Ocular delivery: PEGylation improved vitreous mobility; 17 mol% PEG lipoplexes were stable and mobile in vitreous, while non-PEGylated lipoplexes aggregated. - Immunogenicity: Anti-PEG antibodies and accelerated blood clearance (ABC) occur after repeated PEGylated liposome dosing; 22–25% of PEG-naïve individuals have pre-existing anti-PEG antibodies. PEG alternatives such as HPMA, PVP, and polyglycerol are under investigation.

Interpretation: PEGylation remains a mainstay strategy for improving nanoparticle drug and gene delivery. Its benefits depend on achieving sufficiently dense, brush-like PEG coatings, especially for systemic circulation and mucosal/tissue penetration. PEG molecular weight, density, conformation, core material, and administration route must be optimized together. PEG immunogenicity and accelerated blood clearance are emerging concerns, motivating PEG alternatives and careful dosing strategies. More mechanistic studies on polymeric nanoparticles, beyond liposomes, are needed to guide clinical translation.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Much of the immunogenicity and ABC literature focuses on liposomes; less is known for polymeric nanoparticles. - PEG surface density quantification methods vary and are not standardized. - Optimal PEG properties are context-dependent (cargo, route, disease, species), limiting universal design rules. - Anti-PEG antibodies and accelerated blood clearance remain unresolved and may limit repeated dosing. - Clinical data are limited to a few PEGylated products; long-term safety and large-animal validation are not comprehensively covered.